

## Rita Campanelli, PhD

### Personal data

Name: Rita Campanelli  
Date and place of birth: 24/03/1972, Pavia (Italy)  
Citizenship: Italian  
Work address: Center for the Study of Myelofibrosis,  
Biotechnology Research Area,  
IRCCS Fondazione Policlinico San Matteo,  
p.le Golgi 19, 27100 Pavia (Italy)  
Phone: ++39 0382 502487  
FAX: ++39 0382 502876  
E-mail: [r.campanelli@smatteo.pv.it](mailto:r.campanelli@smatteo.pv.it)



### Education

June 2009: Board Certification in Clinical Pathology at the University of Pavia, thesis title “*Increased bio-availability of TGFβ1 in plasma of patients with primary myelofibrosis*”

May 1998: Bachelor in Biological Sciences at the University of Pavia, thesis title “*Morpho-cytochemical characterization of dendritic cells*”.

### Research experience

From January 2003: research projects on myeloproliferative neoplasms.

1998 to 2002: development of iTag MHC tetramer technology for the monitoring of the anti-tumor response in melanoma patients.

2002: visiting scientist, Institute for Research in Biomedicine, Bellinzona, CH.

### Technical skills and competence

Cell biology techniques, flow cytometry, confocal microscopy. Author or co-author of 40 full peer-reviewed paper, 1 book chapter.

### Grant

2006: IX Congresso Nazionale Società Italiana di Ematologia Sperimentale (SIES) Travel Grant

### Five selected publications

1)Massa M, Canzonieri C, **Campanelli R**, Ornati F, Fois G, Pagella F, Matti E, Buscarini, Danesino C, Rosti V, Olivieri C. *Increase of circulating endothelial cells in patients with Hereditary Hemorrhagic Telangiectasia*. Int J Haematol 2015

2)Campanelli R, Rosti V, Fois G, Bonetti E, Barosi G, Massa M. *CD14brightCD16low intermediate monocytes expressing Tie2 are increased in the peripheral blood of patients with primary myelofibrosis*. Exp Hematol 2014

3)Massa M, Rosti V, Campanelli R, Fois G, Barosi G. *Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib*. Leukemia 2014

4)Rosti V, Villani L, Riboni R, Poletto V, Bonetti E, Tozzi L, Bergamaschi G, Catarsi P, Dalleria E, Novara F, Massa M, Campanelli R, Fois G, Peruzzi B, Lucioni M, Guglielmelli P, Pancrazzi A, fiandrino G, Zuffardi O, Magrini U, Paulli M, Vannucchi AM, Barosi G. *Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation*. Blood 2013

5)Campanelli R, Rosti V, Villani L, Castagno M, Moretti E, Bonetti E, Bergamaschi G, Balduini A, Barosi G, Massa M. *Evaluation of the bioactive and total transforming growth factor beta1 levels in primary myelofibrosis*. Cytokine 52: 100-6, 2011